Cost-Effectiveness of Pembrolizumab With Chemoradiotherapy for Locally Advanced Cervical Cancer
In this economic evaluation of adding concurrent and adjuvant pembrolizumab to first-line treatment of newly diagnosed, locally advanced cervical cancer, this regimen was not cost-effective at current prices despite data demonstrating improved survival with this regimen.
Authors
- Puja Venkat (ORCID: https://orcid.org/0000-0003-4659-3342)
- Ya‐Chen Tina Shih (ORCID: https://orcid.org/0000-0001-7290-3864)
- Michael L. Steinberg (ORCID: https://orcid.org/0000-0002-4292-5824)
- Ann C. Raldow (ORCID: https://orcid.org/0000-0001-8996-6810)
- P.T. Courtney (ORCID: https://orcid.org/0000-0001-7625-3678)
- Alan Lee (ORCID: https://orcid.org/0000-0001-6722-6889)
- Albert J. Chang (ORCID: https://orcid.org/0000-0002-4916-5047)
Institutions
- University of California, Los Angeles (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.0033
- Citations
- 7
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 21.92